Trials: Sustained Virologic Response

Phase 4 N=92 Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C

Hepatitis C · Liver Transplantation

Primary: Number of Participants Sustained Virological Response (SVR) Following Treatment of Hepatitis C Virus (HCV) Infection With Peg-IFN and Ribavirin in Liver Transplanted…

Novartis Pharmaceuticals Results May 2014 38.0% serious AE View details

N/A N=1,082 Evaluation of Rapid Virologic Response Among HCV Patients Treated With PegIntron and Rebetol in Brazil (Study P05427)

Hepatitis C, Chronic · Hepatitis C

Primary: Number of Participants With Rapid Virologic Response After 4 Weeks of Treatment — 551; 32 Participants

Merck Sharp & Dohme LLC Results Jan 2011 5.2% serious AE View details

Phase 3 N=328 Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection

Chronic Hepatitis C

Primary: Percentage of Participants Achieving Sustained Virologic Response (SVR)12 — 91 percentage of participants — p=< 0.001

Gilead Sciences Results May 2014 1.2% serious AE View details

Phase 3 N=249 3-year Follow-up Study in Patients Previously Treated With TMC435-Containing Regimen for the Treatment of Hepatitis C Virus Infection

Hepatitis C

Primary: Percentage of Participants Maintaining SVR at the Last Available Visit — 100 Percentage of participants

Janssen R&D Ireland Results Feb 2017 4.0% serious AE View details

Phase 3 N=723 Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C Patients

Hepatitis C

Primary: Percentage of Participants Maintaining Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Load Below the Level of Quantification (LOQ) Through Week 48 — 96.7; 99.5; 100.0…

Debiopharm International SA Results Aug 2016 2.5% serious AE View details

Phase 3 N=377 A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530

Hepatitis C

Primary: Percentage of Participants Who Maintained a Sustained Virologic Response (SVR) Out of Those Who Achieved SVR12 in a Prior Study With an ABT-493- and/or…

AbbVie Results Sep 2020 0.0% serious AE View details

N/A N=79 Integrated Care for Patients With High Risk Substance Use and Psychiatric Disorder With Chronic Direct Acting Antiviral Treatment

Hepatitis C · Depression · PTSD

Primary: Sustained Viral Response (SVR) — 30; 12.8 percentage of Participants — p=0.07

VA Office of Research and Development Results May 2016 17.7% serious AE View details

Phase 3 N=805 Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease

Hepatitis C, Chronic

Primary: Number of Participants With Sustained Virologic Response (SVR) in the Double-blind (DB) Antiviral Treatment Phase — 32; 97 participants — p=0.0202

GlaxoSmithKline Results May 2012 11.3% serious AE View details

Phase 3 N=715 Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease

Hepatitis C, Chronic

Primary: Number of Participants With Sustained Virologic Response (SVR) in the Double-blind (DB) Antiviral Treatment Phase — 33; 104 participants — p=0.0064

GlaxoSmithKline Results Jul 2012 9.5% serious AE View details

Phase 2 N=30 Short Duration Therapy of Acute Hepatitis C Genotypes 1 or 4

Acute Hepatitis C · HIV

Primary: Sustained Virological Response 12 Weeks Post-treatment (SVR12) — 28 Participants

Institut de Médecine et d'Epidémiologie… Results Jan 2020 6.7% serious AE View details

Phase 3 N=478 A Follow up Study Designed to Obtain Long Term Data on Participants Who Either Achieved a Sustained Virologic Response or Did Not Achieve a Sustained Virologic Response in an AbbVie Sponsored Hepatitis C Study

Hepatitis C

Primary: Percentage of Participants Who Experienced Relapse12overall With and Without New HCV Infection — 0.2; 0.2 percentage of participants

AbbVie (prior sponsor, Abbott) Results Nov 2017 0.0% serious AE View details

Phase 4 N=200 Real World Study: Genotype 1 Chronic Hepatitis C Virus Treatment and Evaluation of Real World SVR and PRO

Hepatitis C, Chronic

Primary: Sustained Virological Response (SVR) at Week 12 — 116; 66 Participants

Kaiser Permanente Results Jan 2021 3.5% serious AE View details

N/A N=496 Study of Patients With Chronic Hepatitis C Infected With HCV LVL G1 and Effect of Peg-Intron Plus Rebetol Treatment (Study P04793)

Hepatitis C

Primary: Number of HCV LVL G1 Participants Who Relapsed — 16 Participants

Merck Sharp & Dohme LLC Results Feb 2010 2.3% serious AE View details

Phase 2 N=288 Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects

Hepatitis · Hepatitis C

Primary: Percentage of Participants With Sustained Viral Response (SVR) at Week 72 — 41.7; 39.6; 45.8 percentage of participants

Pfizer Results Jan 2014 9.0% serious AE View details

Phase 3 N=527 Phase 3 Study of Sofosbuvir and Ribavirin

Hepatitis C

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Stopping All Study Drugs (SVR12) — 67; 67 percentage of participants

Gilead Sciences Results Apr 2014 2.0% serious AE View details

Phase 3 N=741 Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection

Hepatitis C Virus Infection

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 99.0; 0 percentage of participants — p=< 0.001

Gilead Sciences Results Sep 2016 2.0% serious AE View details

Phase 4 N=400 Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection

Hepatitis C · HIV-1-infection · Liver Diseases

Primary: Percentage of Participants With Sustained Virologic Response 12 (SVR12) — 95.0 percentage of participants

Advancing Clinical Therapeutics Globally for… Results Jul 2021 7.8% serious AE View details

Phase 2 N=9 Sofosbuvir/Velpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Undergoing Liver Transplantation

Hepatitis C Virus Infection

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 77.8 Percentage of participants

Gilead Sciences Results Feb 2019 55.6% serious AE View details

Phase 2 N=79 Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant

Hepatitis C Virus Infection

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Cessation of Therapy (SVR12) — 96.2 percentage of participants

Gilead Sciences Results Aug 2018 3.8% serious AE View details

Phase 2 N=59 Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal Disease

Chronic Hepatitis C

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12) — 94.9; 92.0; 100.0; 93.8 percentage of participants

Gilead Sciences Results Nov 2019 18.6% serious AE View details

Phase 1 N=44 Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection

HIV-1 Infection · Hepatitis

Primary: Percentage of Participants With Sustained Virologic Response 12 (SVR12) — 58.8; 100.0 Percentage of participants

Advancing Clinical Therapeutics Globally for… Results Mar 2018 4.6% serious AE View details

Phase 3 N=130 Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection

Hepatitis C Virus Infection

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 93.0 percentage of participants — p=0.009

Gilead Sciences Results Mar 2019 0.8% serious AE View details

Phase 3 N=117 Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen

Hepatitis C Virus Infection

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 85.1; 70.0; 97.9; 91.7 percentage of participants…

Gilead Sciences Results Jul 2018 3.4% serious AE View details

Phase 3 N=51 Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia

Hepatitis C Virus

Primary: Percentage of Participants Who Achieved Sustained Virologic Response (SVR12) at Follow-Up Week 12 — 91.7; 89.7 Percentage of participants

Bristol-Myers Squibb Results Jun 2019 7.8% serious AE View details

Phase 3 N=202 Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)

Chronic Hepatitis C

Primary: Percentage of Participants Achieving SVR12 — 51.0; 72.6 percentage of participants — p=< 0.001

Gilead Sciences Results May 2014 4.0% serious AE View details

Phase 3 N=124 Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C

Hepatitis C

Primary: Percentage of Participants With 12 Week Sustained Virologic Response (SVR12) — 81.7; 42.9 Percentage of participants — p=<0.0001

Bristol-Myers Squibb Results Sep 2015 8.1% serious AE View details

Phase 4 N=15 deLIVER: Direct Acting Antiviral Effects on the Liver

HCV Coinfection · Liver Disease · HIV

Primary: Total Number of HCV-infected Hepatocytes Measured in Liver Tissue Obtained by Liver Biopsy at Day 0 (Pre-treatment) and at Day 7 of Antiviral Therapy — 45; 16; 290; 2…

Johns Hopkins University Results Nov 2020 0.0% serious AE View details

Phase 2 N=106 A Study to Assess the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Participants

Hepatitis C, Chronic

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After End of Study Drug Treatment (SVR12) — 70.6; 100; 93.8 percentage of participants

Janssen-Cilag International NV Results Jan 2017 4.1% serious AE View details

Phase 3 N=40 Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection

Chronic Hepatitis C · Genotype 4 Chronic Hepatitis C

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After End of Treatment (EOT) (SVR12) — 100 percentage of participants

Janssen R&D Ireland Results Nov 2016 0.0% serious AE View details

Phase 3 N=268 Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis

Hepatitis C Virus Infection

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 83.3; 94.3; 87.8 percentage of participants…

Gilead Sciences Results Dec 2016 17.6% serious AE View details

Clinical Trial Search

Phase 4 N=92 Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C

N/A N=1,082 Evaluation of Rapid Virologic Response Among HCV Patients Treated With PegIntron and Rebetol in Brazil (Study P05427)

Phase 3 N=328 Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection

Phase 3 N=249 3-year Follow-up Study in Patients Previously Treated With TMC435-Containing Regimen for the Treatment of Hepatitis C Virus Infection

Phase 3 N=723 Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C Patients

Phase 3 N=377 A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530

N/A N=79 Integrated Care for Patients With High Risk Substance Use and Psychiatric Disorder With Chronic Direct Acting Antiviral Treatment

Phase 3 N=805 Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease

Phase 3 N=715 Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease

Phase 2 N=30 Short Duration Therapy of Acute Hepatitis C Genotypes 1 or 4

Phase 3 N=478 A Follow up Study Designed to Obtain Long Term Data on Participants Who Either Achieved a Sustained Virologic Response or Did Not Achieve a Sustained Virologic Response in an AbbVie Sponsored Hepatitis C Study

Phase 4 N=200 Real World Study: Genotype 1 Chronic Hepatitis C Virus Treatment and Evaluation of Real World SVR and PRO

N/A N=496 Study of Patients With Chronic Hepatitis C Infected With HCV LVL G1 and Effect of Peg-Intron Plus Rebetol Treatment (Study P04793)

Phase 2 N=288 Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects

Phase 3 N=527 Phase 3 Study of Sofosbuvir and Ribavirin

Phase 3 N=741 Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection

Phase 4 N=400 Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection

Phase 2 N=9 Sofosbuvir/Velpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Undergoing Liver Transplantation

Phase 2 N=79 Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant

Phase 2 N=59 Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal Disease

Phase 1 N=44 Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection

Phase 3 N=130 Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection

Phase 3 N=117 Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen

Phase 3 N=51 Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia

Phase 3 N=202 Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)

Phase 3 N=124 Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C

Phase 4 N=15 deLIVER: Direct Acting Antiviral Effects on the Liver

Phase 2 N=106 A Study to Assess the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Participants

Phase 3 N=40 Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection

Phase 3 N=268 Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis